AstraZeneca Partners for T1DM Cell Therapy; New Lilly Care Trial

Two cardiometabolic-related news items have been observed: AstraZeneca and Quell Therapeutics announced a collaboration to develop, manufacture, and commercialize autologous, engineered Treg cell therapies for T1DM and IBD; and Lilly initiated a trial evaluating adherence and glucose control of its connected Tempo pen system in conjunction with Dexcom and Glooko (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how AZ’s collaboration fits with another one of its recent partnerships.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.